Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Background: Many studies show that camrelizumab combination therapy can significantly improve progression-free survival (PFS) and overall (OS) in non-small cell lung cancer (NSCLC). However, the time of to market is short, there no systematic evaluation camrelizumab-based comprehensive treatment NSCLC. Objectives: To systematically evaluate efficacy safety comprehensively treating Design: A review meta-analysis. Data sources methods: Databases, including PubMed, Web Science, Embase, Cochrane, were searched by computer before August 2023 based on Preferred Reporting Items for Systematic Review Meta-Analysis (PRISMA) guidelines, reports NSCLC collected, RevMan 5.4 software was employed meta-analysis finally. Results: Totally, 5 RCTs, 2 cohort studies, 12 single-arm included. The results revealed that, compared with without camrelizumab, considerably extended OS (hazard ratio (HR) = 0.60, 95% confidence interval (CI): (0.44–0.82), p < 0.01), PFS (HR 0.42, CI: (0.28–0.63), event-free (EFS) 0.55, (0.44–0.68), 0.01). median objective response rate 41% (95% 28%–53%), disease control 84% 78%–89%). Furthermore, terms occurrence grades 3–5 adverse events, incidence neutropenia lower group than group, while leukopenia rash higher significant difference other events. Among events did not exceed 10%. Conclusion: Treatment combined effectively prolong OS, PFS, EFS patients good safety, chemotherapy an effective option patients.

Language: Английский

Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(11), P. 1221 - 1232

Published: Oct. 26, 2024

Introduction Locally advanced esophageal cancer (EC) has poor prognosis. Preliminary clinical studies have demonstrated the synergistic efficacy of radiotherapy combined with immunotherapy in EC. Adjusting target volume to protect immune function favors immunotherapy. However, there is no clear consensus on exact definition EC volume.

Language: Английский